Inspire Advisors LLC Buys New Holdings in Insulet Corporation $PODD

Inspire Advisors LLC purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,292 shares of the medical instruments supplier’s stock, valued at approximately $720,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Insulet by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock worth $2,735,991,000 after purchasing an additional 39,403 shares during the period. Geode Capital Management LLC lifted its position in Insulet by 3.1% during the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after buying an additional 58,309 shares in the last quarter. American Century Companies Inc. lifted its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares in the last quarter. Groupama Asset Managment grew its stake in Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after buying an additional 3,759 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock worth $177,096,000 after acquiring an additional 27,408 shares in the last quarter.

Insulet Trading Up 1.7%

NASDAQ:PODD opened at $333.47 on Wednesday. The stock has a market cap of $23.46 billion, a price-to-earnings ratio of 101.36, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a one year low of $230.05 and a one year high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business’s 50-day simple moving average is $322.76 and its 200 day simple moving average is $313.97.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same quarter last year, the firm earned $1.08 EPS. Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PODD has been the topic of several recent research reports. Stifel Nicolaus assumed coverage on shares of Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price on the stock. Canaccord Genuity Group boosted their price objective on Insulet from $399.00 to $428.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group raised their target price on Insulet from $375.00 to $388.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Wolfe Research boosted their price target on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.